Quarterly ResultAug 12, 2026, 04:18 PM
Cardiol Therapeutics Q2 Net Loss $6.08M; Cash $26.08M
AI Summary
Cardiol Therapeutics reported a net loss of $6.08 million for the second quarter of 2026, an improvement from $8.35 million in the same period last year. For the six months ended June 30, 2026, the net loss was $16.90 million, slightly higher than $16.64 million in the prior year, but basic and diluted net loss per share improved to $0.15 from $0.20. The company significantly bolstered its cash position to $26.08 million, driven by $16.08 million in financing activities, including a unit financing and warrant exercises. Research and development expenses increased by 25.53% to $8.15 million for the six-month period, reflecting continued investment in its pipeline.
Key Highlights
- Net loss for Q2 2026 was $6.08 million, compared to $8.35 million in Q2 2025.
- Net loss for the six months ended June 30, 2026, was $16.90 million, up from $16.64 million in the prior year.
- Cash and cash equivalents increased to $26.08 million as of June 30, 2026, from $21.42 million at December 31, 2025.
- Basic and diluted net loss per share for the six months was $0.15, an improvement from $0.20 in the prior year.
- Research and development expenses for the six months rose to $8.15 million from $6.49 million year-over-year.
- Net cash provided by financing activities for the six months was $16.08 million, primarily from a unit financing and warrant exercises.
- Total equity increased to $24.03 million as of June 30, 2026, from $17.88 million at December 31, 2025.
Price Impact
More from CRDL